Roll-over Study to Allow Continued Access to Ribociclib

Key Inclusion Criteria:

• Signed informed consent must be obtained prior to participation in the study.

• Participant is currently participating in a Novartis sponsored global study (parentstudy), receiving treatment with ribociclib in combination with other drugs and theparent study has fulfilled its primary objective(s).

• Willingness and ability to comply with scheduled visits, treatment plans and anyother study procedures.

• Participant must have been receiving treatment with ribociclib for at least 6 cyclesin the parent study.

• Participant must have evidence of clinical benefit as determined by theInvestigator.

Key Exclusion Criteria:

• Permanent discontinuation of ribociclib in the parent study due to toxicity ordisease progression, non-compliance to study procedures, withdrawal of consent orany other reason as stipulated in parent protocol.

• Participant currently has unresolved toxicities for which ribociclib dosing has beeninterrupted in the parent study (participants meeting all other eligibility criteriamay be enrolled once toxicities have resolved to allow ribociclib dosing to resume).

• Local access to commercially available ribociclib and reimbursed (except for USenrolled participants from parent protocol CLEE011A2404 meeting all othereligibility criteria).

• Women of child-bearing potential defined as all women physiologically capable ofbecoming pregnant, unless they are using highly effective methods of contraceptionduring the study treatment and for 21 days after stopping the treatment. Highlyeffective contraception methods include:

1. Total abstinence

2. Female sterilization

3. Male partner sterilization

4. Placement of an intrauterine device (IUD)

• Male contraception during ribociclib use by male participants is not required unlessit is necessary due to the safety profile of other medications a participant istaking or by local regulations.

Other protocol-defined inclusion/exclusion criteria may apply.